Physician profile
Thaw Poon
NPI 1912944349
$4,166.12
in general payments reported to CMS, 2019-2025
22 companies · $124 in 2025
The $124 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,634 · 2020: $202 · 2021: $320 · 2022: $307 · 2023: $768 · 2024: $812 · 2025: $124.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,704.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,704.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $726.34 | 2019-2025 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $609.03 | 2019-2024 | Breztri, Farxiga |
| Abbvie INC. | $582.15 | 2021-2025 | |
| Lilly USA, LLC | $503.58 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| E.R. Squibb & Sons, L.L.C. | $360.73 | 2022-2024 | Camzyos, Eliquis |
| Spineology INC. | $210.69 | 2021-2023 | Optimesh Expandable Interbody Fusion System |
| Pfizer INC. | $197.38 | 2023-2024 | |
| Amgen INC. | $182.32 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $143.08 | 2019-2024 | Jardiance, Synjardy, Tradjenta |
| Horizon Therapeutics Plc | $122.46 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $118.95 | 2021 | |
| Allergan, INC. | $76.49 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $74.07 | 2019-2024 | |
| Genentech USA, INC. | $46.34 | 2019 | |
| Abbott Laboratories | $43.98 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $35.42 | 2019-2024 | Trelegy Ellipta |
| Sunovion Pharmaceuticals INC. | $33.07 | 2019 | |
| Janssen Pharmaceuticals, INC | $29.37 | 2019 | |
| Phathom Pharmaceuticals, INC. | $24.15 | 2024 | Voquezna |
| Incyte Corporation | $23.07 | 2025 | Opzelura |
| Teva Pharmaceuticals USA, INC. | $12.32 | 2019 | |
| Merck Sharp & Dohme LLC | $11.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thaw Poon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.